By REUTERS
NYT Business
Novartis's shift into high-tech drugs won praise for giving new options to patients but criticism for prices that may run into the millions of dollars as the Swiss drugmaker faced investors at its annual general meeting on Thursday.
Published date: February 28, 2019 at 12:47PM
Reuters
New York Times article
No comments:
Post a Comment